-
Mashup Score: 68Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients - American Journal of Cardiovascular Drugs - 2 year(s) ago
Patients with coronary artery disease (CAD) presenting with acute coronary syndrome or undergoing coronary stenting are indicated to treatment with dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor. The management of patients with CAD who present with a complex clinical profile due to multiple comorbidities, and/or undergoing complex interventional procedures,…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Is it Time for Single-Pill Combinations in Dyslipidemia? - American Journal of Cardiovascular Drugs - 3 year(s) ago
Despite the availability of lipid-lowering therapies (LLTs) that are safe and effective, the overall rate of low-density lipoprotein cholesterol (LDL-C) control at a population level in real-life studies is low. Higher-intensity treatment, earlier intervention, and longer-term treatment have all been shown to improve outcomes. However, in clinical practice, actual exposure to LLT is a product of…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
Objectives The objective of this study was to evaluate a US hospital’s cost implications and outcomes of cangrelor use in percutaneous coronary intervention (PCI) patients with two or more angiographic high-risk features (HRFs), including avoidance of oral P2Y12 inhibitor pretreatment in patients requiring cardiac surgery. Intravenous cangrelor provides direct, immediate onset and rapid-offset…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View - 3 year(s) ago
In the 2020 European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndromes (NSTE-ACS), the experts proposed to put an end to the equipoise of ticagrelor and prasugrel in addition to aspirin in patients with NSTE-ACS who proceed to percutaneous coronary intervention (PCI). They gave a strong level of recommendation (IIa) in favor of prasugrel over ticagrelor in…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis - 3 year(s) ago
Background Evidence from recent trials has shown conflicting results in terms of the utility of colchicine in patients with coronary artery disease (CAD). Methods Multiple databases were queried to identify all randomized controlled trials (RCTs) comparing the merits of colchicine in patients with acute coronary syndrome (ACS) or stable CAD. The pooled relative risk ratio (RR) of major adverse…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 31
Patients with coronary artery disease (CAD) presenting with acute coronary syndrome or undergoing coronary stenting are indicated to treatment with dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor. The management of patients with CAD who present with a complex clinical profile due to multiple comorbidities, and/or undergoing complex interventional procedures,…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View - 3 year(s) ago
In the 2020 European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndromes (NSTE-ACS), the experts proposed to put an end to the equipoise of ticagrelor and prasugrel in addition to aspirin in patients with NSTE-ACS who proceed to percutaneous coronary intervention (PCI). They gave a strong level of recommendation (IIa) in favor of prasugrel over ticagrelor in…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View - 3 year(s) ago
In the 2020 European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndromes (NSTE-ACS), the experts proposed to put an end to the equipoise of ticagrelor and prasugrel in addition to aspirin in patients with NSTE-ACS who proceed to percutaneous coronary intervention (PCI). They gave a strong level of recommendation (IIa) in favor of prasugrel over ticagrelor in…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry - 3 year(s) ago
Background Limited data are available concerning differences in clinical outcomes for real-life patients treated with ticagrelor versus prasugrel after percutaneous coronary intervention (PCI). Objective Our objective was to determine and compare the efficacy and safety of ticagrelor and prasugrel in a real-world population. Methods RENAMI was a retrospective, observational registry including the…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7NSTE-ACS ESC Guidelines Recommend Prasugrel as the Preferred P2Y12 Inhibitor: A Contrarian View - 3 year(s) ago
In the 2020 European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndromes (NSTE-ACS), the experts proposed to put an end to the equipoise of ticagrelor and prasugrel in addition to aspirin in patients with NSTE-ACS who proceed to percutaneous coronary intervention (PCI). They gave a strong level of recommendation (IIa) in favor of prasugrel over ticagrelor in…
Categories: Cardiologists, Latest HeadlinesTweet
RT @SABOURETCardio: The link https://t.co/J9iCbGbF9y #DAPT #cardiotwitter #thrombosis Chief Editor : Amitabh Prakash. https://t.co/oYIEQ0t…